However, additional biochemical and clinical studies designed to define a range or threshold level of AGAT inactivation, for which to target with modulating strategies, will undoubtedly facilitate the development of temozolomide dose-schedules with superior therapeutic indices in those tumour sites, where methylating agents have utility (Friedman et al, 1998). This evidence concerns the gene GATM and neoplasm.